Abstract mRNA-based drugs have tremendous potential as clinical treatments, however, a
major challenge in realizing this drug class will promise to develop methods for safely …

In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool
for vaccination. In the following decades, an improved understanding of the mRNA …

Synthetic mRNA represents an exciting cancer vaccine technology for the implementation of
effective cancer immunotherapy. However, inefficient in vivo mRNA delivery along with a …

In late 2020, the US Food and Drug Administration (FDA) approved a lipid-based mRNA
vaccine for the prevention of COVID-19, which has pushed this field to be more closely …

Comparative oncology clinical trials play an important and growing role in cancer research
and drug development efforts. These trials, typically conducted in companion (pet) dogs …

Nanoparticulate drug delivery systems (Nano-DDSs) have emerged as possible solution to
the obstacles of anticancer drug delivery. However, the clinical outcomes and translation are …

Tumor vaccination is a promising approach for tumor immunotherapy because it presents
high specificity and few side effects. However, tumor vaccines that contain only a single …

Cancer immunotherapies including cancer vaccines, immune checkpoint blockade or
chimeric antigen receptor T cells have been exploited as the attractive treatment modalities …

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …

The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and
mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics …